Our observations provide additional rationale for building on previous studies [18, 24, 29] to further investigate LAG3-FGL1 and CXCR4-CXCL12 targeting strategies especially in the setting of liver metastatic cancers. Here, CXCL12 is linked to metastatic malignant neoplasm.